Has Novo Nordisk Wegovy just delivered the prescription surge that forces Wall Street to rethink the entire obesity trade?
How Fast Is Novo Nordisk Wegovy Growing?
Novo Nordisk Wegovy’s oral tablet is rewriting growth expectations. Just 22 weeks after U.S. launch in January 2026, the drug has already generated approximately 3 million prescriptions—surpassing analyst forecasts by a wide margin. For context, Eli Lilly’s competing oral GLP-1, Foundayo, launched concurrently but has yet to reach comparable velocity. Berenberg analysts credit this acceleration to strong physician adoption, favorable payer coverage, and seamless switching from injectable semaglutide. The momentum is so pronounced that Berenberg revised its 2026 oral Wegovy sales forecast to 18 billion Danish kroner—nearly 64% above the consensus of 11 billion kroner.
What Does Berenberg’s Upgrade Mean for U.S. Investors?
Berenberg lifted its price target for Novo Nordisk from 300 to 325 DKK—equivalent to roughly $43.49 at current exchange rates—while maintaining its ‘Buy’ rating. That implies ~14% upside from the current trading level of $43.18. The upgrade reflects confidence not only in Wegovy’s oral form but also in the recently launched Wegovy HD (7.2 mg single-dose pen), where 80% of users transitioned from lower-dose regimens—effectively locking in retention and reducing churn to Eli Lilly. With the U.S. accounting for over half of global Wegovy prescriptions, this isn’t just a European story—it’s a Wall Street catalyst.
Is the Growth Sustainable Beyond the U.S.?
Yes—and the international rollout is already underway. Novo Nordisk confirmed plans to launch the oral Wegovy tablet in the United Arab Emirates this summer, with a China regulatory filing expected ‘very soon’, per CEO Mike Doustdar. That aligns with the European Medicines Agency’s recent positive opinion for the oral formulation—a key step toward EU commercialization. Meanwhile, the CHMP also backed the high-dose Wegovy 7.2 mg pen for EU approval, targeting a Q3 2026 launch. These parallel approvals underscore Novo Nordisk’s ability to scale across geographies, a critical advantage as U.S. pricing pressure intensifies under Medicare Part D negotiations.
What About Risks Beyond the Balance Sheet?
A cyberattack by FulcrumSec compromised clinical trial data—but Novo Nordisk confirmed no patient identifiers were exposed, and operations remain uninterrupted. Clinical Trials Arena reported the breach involved anonymized trial information, and authorities have been notified. While cybersecurity is now a permanent line item for pharma investors, the market’s muted reaction—NVO fell just 0.78% today despite the news—suggests investors prioritize commercial execution over episodic IT incidents. That confidence is reinforced by Novo Nordisk’s $15 billion share repurchase program, over one-third of which has already been deployed, signaling strong free cash flow and management conviction.
How Does This Fit Into the Broader Obesity Market?
Novo Nordisk Wegovy isn’t operating in a vacuum. Eli Lilly’s Zepbound and Foundayo are gaining traction, and new entrants like Apple-backed biotech partnerships and Moderna’s metabolic pipeline are emerging. Yet Novo Nordisk maintains commanding share: over 50% of global weekly Wegovy prescriptions—116,000 per week—still flow through U.S. channels alone. With CagriSema and Mim8 nearing key regulatory milestones this fall, the company is building a multi-asset obesity and hemophilia franchise. At a 13% discount to large-cap pharma peers on forward P/E, the valuation gap appears increasingly unjustified given the growth inflection.
Related Coverage: Novo Nordisk Wegovy Faces a Warning in the Obesity Race explores competitive dynamics ahead of Eli Lilly’s next clinical readouts. Meanwhile, Moderna Flu Vaccine: FDA Briefing Sets Up Key Vote highlights how regulatory momentum in adjacent therapeutic areas is reshaping biotech investor sentiment across the NASDAQ.
The oral Wegovy tablet is now the single largest growth driver for Novo Nordisk in the U.S., with uptake exceeding our most aggressive models.— Berenberg Analyst Team
Novo Nordisk Wegovy is no longer just a weight-loss pill—it’s the cornerstone of a global commercial and pipeline renaissance. For U.S. investors, the combination of accelerating prescriptions, international expansion, and disciplined capital allocation makes Novo Nordisk a compelling overweight in healthcare portfolios. The next catalyst arrives September 21, when Novo Nordisk hosts its Capital Markets Day—likely to detail CagriSema’s Phase 3 obesity data and commercial launch strategy. With Wegovy’s oral and high-dose formulations gaining traction, the path to higher earnings revisions has never been clearer.
